Son of Neurontin Meets the Fibromyalgia Epidemic


Who says technology transfer doesn’t pay?

Pregablin, discovered by Northwestern University chemist Richard Silverman in 1989 to become Pfizer’s Lyrica, earned the university a cool $700 million when it sold royalties in Dec. 2007.

The nerve pain-cum-seizure pill is funding the $100 million Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics–currently a hole in the ground on the way to the student union–which will employ 245 this fall. Views of Lake Michigan and the duck pond included.

And, thanks to FDA approval in 2007 of Lyrica as the first US drug for the pain condition fibromyalgia, it may earn as much as its molecular relative–Pfizer’s Neurontin (gabapentin)–which made $3 billion a year before its patent ran out in 2004.

No wonder they call Lyrica son of Neurontin.

Of course there have been setbacks on the road to marketing Lyrica.

In 2001, Pfizer had to freeze pain trials and restrict pregablin in patients when test mice developed cancerous tumors. Profit warning! But when rats tests were okay, Toni Hoover, a vice president with Pfizer’s now defunct Ann Arbor, MI labs sounded the all clear. “The FDA has found that the benefit of taking the drug outweighs any risk,” she told the Detroit News.

Pfizer brass failed to embrace Silverman the way it embraced the $564 million he made for them in Lyrica’s first three months. (“They had a launch party for the drug, and I asked to come. Nope. No party for me. They take your stuff and tell you to go away,” he told the Chicago Tribune.)

And Lyrica’s not approved for the “social phobia” detailed in Pfizer original marketing plans. Yet.

But as long as pharma can get a drug approved in advance of its uses and people will take an antipsychotic for the blues or a seizure med for migraines, Lyrica has a future.

Initial articles about Lyrica which, like Neurontin, is an anti-seizure drug that modulates calcium channels to dampen the excitability of nerve endings, were positive.

“Well tolerated,” said Arthritis and Rheumatism in 2005.

“Proven efficacy” and “No new adverse events,” said Drugs of Today in 2005 and 2007.

“Durability of effect for relieving FM pain,” said the journal Pain in 2008.

Unfortunately the articles were all written by Pfizer paid doctors.

Actual users of Lyrica report memory loss, mental confusion, extreme weight gain, hair loss, impaired driving, disorientation, twitching and a lot of I’d-rather-have-my-fibro-symptoms-back-if-this-is-the-cure on askapatient.com. P.S. There are two deaths.

Of course its no secret that Pfizer’s blockbusters Viagra, Zoloft and Lipitor are history and its pipeline is bare. In January, it announced it was losing 800 of its researchers and buying Wyeth (no danger of getting new researchers there.)

Nor can its gravy train of antibiotics in food animals–pun intended–last much longer with residues found in meat, water and even crops and world recognition of antibiotic resistance.

Just as people were forgetting that Pfizer paid $430 million in 2004 for criminally promoting Neurontin for bipolar disorder, attention-deficit disorder, restless legs syndrome and other unapproved disorders, an article in the January 9 New England Journal of Medicine titled “The Neurontin Legacy–Marketing through Misinformation and Manipulation,” shows it’s déjà vu all over again at Pfizer.

Nor is Lyrica the only game in town anymore for fibromyalgia since the FDA approved Lilly’s antidepressant Cymbalta in 2008 and Forest Laboratories’ antidepressant Savella in January. Now Americans can choose between an antidepressant with a black box warning for suicide and a seizure medication for a disease they didn’t know they had–or was an epidemic–ten years ago.

Lyrica itself was slated for an FDA black box suicide warning in 2008. A 92-page appeal from Pfizer last summer called the suicide stats “an exaggeration of risk that is introduced by ascertainment bias” and cautioned against “overwarning…patients and prescribers” so that they “underestimate the risks of declining treatment.” Especially risks for Pfizer.

As Northwestern students negotiate the snow and construction at the future home of the Richard and Barbara Silverman Hall for Molecular Therapeutics & Diagnostics, any pain they feel is from all-nighters, all-you-can-drink nights and the cold–not fibromyalgia. Few will remember Lyrica when classes start in the new science hall. Nor can a building be withdrawn.

MARTHA ROSENBERG is a columnist/cartoonist who writes about public health. She can be reached  at martharosenberg@sbcglobal.net



Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

October 07, 2015
Nancy Scheper-Hughes
Witness to a Troubled Saint-Making: Junipero Serra and the Theology of Failure
Luciana Bohne
The Double-Speak of American Civilian Humanitarianism
Joyce Nelson
TPP: Big Pharma’s Big Deal
Jonathan Cook
Israel Lights the Touchpaper at Al-Aqsa Again
Joseph Natoli
The Wreckage in Sight We Fail To See
Piero Gleijeses
Jorge Risquet: the Brother I Never Had
Andrew Stewart
Do #BlackLivesMatter to Dunkin’ Donuts?
Rajesh Makwana
#GlobalGoals? The Truth About Poverty and How to Address It
Joan Berezin
Elections 2016: A New Opening or Business as Usual?
Dave Randle
The Man Who Sold Motown to the World
Adam Bartley
“Shameless”: Hillary Clinton, Human Rights and China
Binoy Kampmark
The Killings in Oregon: Business as Usual
Harvey Wasserman
Why Bernie and Hillary Must Address America’s Dying Nuke Reactors
Tom H. Hastings
Unarmed Cops and a Can-do Culture of Nonviolence
October 06, 2015
Vijay Prashad
Afghanistan, the Terrible War: Money for Nothing
Mike Whitney
How Putin will Win in Syria
Paul Street
Yes, There is an Imperialist Ruling Class
Paul Craig Roberts
American Vice
Kathy Kelly
Bombing Hospitals: 22 People Killed by US Airstrike on Doctors Without Borders Hospital in Kunduz, Afghanistan
Ron Jacobs
Patti Smith and the Beauty of Memory
David Macaray
Coal Executive Finally Brought Up on Criminal Charges
Norman Pollack
Cold War Rhetoric: The Kept Intelligentsia
Cecil Brown
The Firing This Time: School Shootings and James Baldwin’s Final Message
Roger Annis
The Canadian Election and the Global Climate Crisis
W. T. Whitney
Why is the US Government Persecuting IFCO/Pastors for Peace Humanitarian Organization?
Jesse Jackson
Alabama’s New Jim Crow Far From Subtle
Joe Ramsey
After Umpqua: Does America Have a Gun Problem….or a Dying Capitalist Empire Problem?
Murray Dobbin
Rise Up, Precariat! Cheap Labour is Over
October 05, 2015
Michael Hudson
Parasites in the Body Economic: the Disasters of Neoliberalism
Patrick Cockburn
Why We Should Welcome Russia’s Entry Into Syrian War
Kristine Mattis
GMO Propaganda and the Sociology of Science
Heidi Morrison
Well-Intentioned Islamophobia
Ralph Nader
Monsanto and Its Promoters vs. Freedom of Information
Arturo Desimone
Retro-Colonialism: the Exportation of Austerity as War By Other Means
Robert M. Nelson
Noted Argentine Chemist Warns of Climate Disaster
Matt Peppe
Misrepresentation of the Colombian Conflict
Barbara Dorris
Pope Sympathizes More with Bishops, Less with Victims
Clancy Sigal
I’m Not a Scientologist, But I Wish TV Shrinks Would Just Shut Up
Chris Zinda
Get Outta’ Dodge: the State of the Constitution Down in Dixie
Eileen Applebaum
Family and Medical Leave Insurance, Not Tax Credits, Will Help Families
Pierre-Damien Mvuyekure
“Boxing on Paper” for the Nation of Islam, Black Nationalism, and the Black Athlete: a Review of “The Complete Muhammad Ali” by Ishmael Reed
Lawrence Ware
Michael Vick and the Hypocrisy of NFL Fans
Gary Corseri - Charles Orloski
Poets’ Talk: Pope Francis, Masilo, Marc Beaudin, et. al.
Weekend Edition
October 2-4, 2015
Henry Giroux
Murder, USA: Why Politicians Have Blood on Their Hands
Mike Whitney
Putin’s Lightning War in Syria